EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE (COVID-19 Vaccine, mRNA)

NEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and ...

Moderna (MRNA) Q3 2024 Earnings Call Transcript

Revenue -- $1.9 billion reported for the quarter, compared to prior sales cycles impacted by earlier U.S. COVID-19 vaccine ...

Moderna, Inc.: EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE

NEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and mRESVIA (Respiratory Syncytial Virus Vaccine)mNEXSPIKE will be available in the E ...
pharmaphorum

CHMP decision levels the playing field for GSK's RSV jab

The recommendation by the CHMP should now result in approval of Arexvy in the broader age range in February next year, and ...
KFGO

GSK gets EU regulator backing for expanded use of RSV vaccine

GSK said on Friday a panel ‍of the European Medicines Agency had backed the use of its ‌respiratory syncytial ‌virus (RSV) ...
Seeking Alpha

Moderna Analyst Day Highlights Pipeline Progress and Business Strategy Updates

Expects to expand seasonal vaccine franchise from three to up to six approved products by 2028 Targets readouts from nine ongoing Phase 2 and Phase 3 clinical studies in its oncology pipeline, ...
Detroit Free Press

Moderna Analyst Day Highlights Pipeline Progress and Business Strategy Updates

Targets readouts from nine ongoing Phase 2 and Phase 3 clinical studies in its oncology pipeline, including three Phase 3 programs for intismeran autogene Further improves 2026 and 2027 expected GAAP ...